This federal Project Grant award from the National Institute on Aging (NIA) under the Aging Research program (CFDA 93.866) provides $2,015,762 to Texas A&M AgriLife Research to conduct the "Test of Rapamycin in Aging Dogs" (TRIAD) clinical trial. The primary objectives are to determine whether weekly rapamycin treatment increases lifespan and improves health outcomes in 580 companion dogs. Specific aims include evaluating the impact of rapamycin on measures such as cancer, infectious disease, immune function, sensory loss, kidney disease, joint issues, and cognitive decline. The project will also assess changes in physical, neurological, and cardiovascular function in the dogs. With existing infrastructure and protocols already in place, the 3-year study began in Dec 2024 and will leverage Texas A&M's expertise in veterinary research to advance understanding of geroprotective interventions for aging.